The American Kratom Association (AKA) has criticized the Ohio Board of Pharmacy for its unanimous decision to classify natural kratom’s key compound, mitragynine, as a controlled substance — a move the group calls “scientifically unjustified.”
In a statement, the AKA expressed deep concern that the Board reached its decision “without a single question” during deliberations, relying on what it described as outdated federal data long rejected by health officials. Both HHS Secretary Robert F. Kennedy, Jr. and FDA Commissioner Dr. Marty Makary have clarified that enforcement should target synthetic 7-hydroxymitragynine products, not natural kratom leaf. The AKA has urged Ohio lawmakers to intervene and reverse the decision, calling it a threat to consumers who use kratom as a safer alternative to opioids.
Read the full statement from the American Kratom Association.